{"id":"granulocyte-colony-stimulating-growth-factor","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Bone pain"},{"rate":"10-20","effect":"Headache"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Fever"},{"rate":"5-10","effect":"Splenomegaly"},{"rate":"5-10","effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"G-CSF is a cytokine that binds to G-CSF receptors on hematopoietic progenitor cells in the bone marrow, promoting their proliferation, differentiation, and maturation into neutrophils. It enhances neutrophil mobilization from the bone marrow into peripheral circulation, thereby increasing absolute neutrophil counts. This mechanism is used clinically to mitigate chemotherapy-induced neutropenia and support immune recovery.","oneSentence":"Granulocyte-colony stimulating factor (G-CSF) stimulates the bone marrow to produce and release neutrophils, increasing white blood cell counts.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:24.029Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced neutropenia"},{"name":"Severe chronic neutropenia"},{"name":"Mobilization of peripheral blood progenitor cells for stem cell transplantation"}]},"trialDetails":[{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":"Primary Mediastinal Large B-Cell Lymphoma","enrollment":244},{"nctId":"NCT02436707","phase":"PHASE2","title":"Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2015-10-27","conditions":"Lymphoma","enrollment":129},{"nctId":"NCT01553214","phase":"PHASE4","title":"Improving White Blood Cell Collection From Healthy Donors","status":"RECRUITING","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2012-12-31","conditions":"Allogeneic Granulocyte Donation","enrollment":1000},{"nctId":"NCT05139017","phase":"PHASE2, PHASE3","title":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-14","conditions":"DLBCL, Diffuse Large B-Cell Lymphoma","enrollment":290},{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT07012044","phase":"PHASE1","title":"A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-10-30","conditions":"Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":47},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":97},{"nctId":"NCT00001529","phase":"","title":"Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1996-03-18","conditions":"Graft-Versus-Host Disease, Graft-versus-leukemia, Donor Apheresis","enrollment":500},{"nctId":"NCT02015013","phase":"PHASE2","title":"Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-01-15","conditions":"Idiopathic CD4-Positive, T-Lymphocytopenia","enrollment":40},{"nctId":"NCT06325709","phase":"PHASE1, PHASE2","title":"Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-04-17","conditions":"Chronic Granulomatous Disease (CGD), X-Linked Chronic Granulomatous Disease","enrollment":10},{"nctId":"NCT07224100","phase":"PHASE2","title":"Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-15","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1, Lymphoblastic Lymphoma","enrollment":33},{"nctId":"NCT06450041","phase":"PHASE2","title":"NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial","status":"RECRUITING","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2024-12-16","conditions":"Neuroblastoma","enrollment":62},{"nctId":"NCT06528691","phase":"PHASE2","title":"Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2026-04","conditions":"High Grade Glioma, CNS Tumor","enrollment":52},{"nctId":"NCT05436418","phase":"PHASE1, PHASE2","title":"The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-18","conditions":"Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation","enrollment":260},{"nctId":"NCT05796570","phase":"PHASE2","title":"A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies","status":"RECRUITING","sponsor":"Franziska Wachter","startDate":"2023-04-19","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloid Malignancies","enrollment":37},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT04936529","phase":"PHASE2","title":"A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-08-02","conditions":"Neuroblastoma","enrollment":286},{"nctId":"NCT06738368","phase":"PHASE2","title":"Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-01","conditions":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT05357482","phase":"PHASE1, PHASE2","title":"Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-05-12","conditions":"Sickle Cell Anemia, Beta Thalassemia","enrollment":40},{"nctId":"NCT06752694","phase":"PHASE2","title":"Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-09-25","conditions":"Aplastic Anemia","enrollment":20},{"nctId":"NCT06059391","phase":"PHASE2","title":"CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-07-12","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia","enrollment":216},{"nctId":"NCT07257419","phase":"PHASE1","title":"CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2026-03-03","conditions":"Relapsed Pediatric ALL, Hematopoietic Cell Transplantation, Hematologic Malignancy","enrollment":60},{"nctId":"NCT06254326","phase":"PHASE1","title":"ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2024-09-19","conditions":"Recurrent Oligodendroglioma, Progressive Oligodendroglioma","enrollment":12},{"nctId":"NCT04375631","phase":"PHASE1","title":"CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-12-03","conditions":"Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome","enrollment":120},{"nctId":"NCT03214562","phase":"PHASE1, PHASE2","title":"Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-09-26","conditions":"High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":116},{"nctId":"NCT04144023","phase":"PHASE1","title":"A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2019-06-27","conditions":"Breast Ductal Carcinoma In Situ","enrollment":43},{"nctId":"NCT03849651","phase":"PHASE2","title":"TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-01-31","conditions":"Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)","enrollment":69},{"nctId":"NCT07044544","phase":"PHASE1","title":"Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-07-17","conditions":"Myeloid Malignancy, Hematologic Malignancy, Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT04238819","phase":"PHASE1, PHASE2","title":"A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-11-09","conditions":"Relapsed Solid Tumor, Refractory Solid Tumor","enrollment":47},{"nctId":"NCT07441967","phase":"PHASE2","title":"The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-02-20","conditions":"Hematologic Malignancies","enrollment":44},{"nctId":"NCT04195633","phase":"PHASE2","title":"Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-01-25","conditions":"Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":60},{"nctId":"NCT06942039","phase":"EARLY_PHASE1","title":"Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation","status":"RECRUITING","sponsor":"C17 Council","startDate":"2025-09-23","conditions":"CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor","enrollment":15},{"nctId":"NCT04684368","phase":"PHASE2","title":"A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2021-07-13","conditions":"Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma","enrollment":160},{"nctId":"NCT05589896","phase":"PHASE1, PHASE2","title":"A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies","status":"RECRUITING","sponsor":"Ossium Health, Inc.","startDate":"2024-08-16","conditions":"Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":12},{"nctId":"NCT05170828","phase":"PHASE1","title":"Cryopreserved MMUD BM With PTCy for Hematologic Malignancies","status":"WITHDRAWN","sponsor":"Ossium Health, Inc.","startDate":"2022-09","conditions":"Acute Leukemia, Myelodysplastic Syndromes, T-lymphoblastic Lymphoma","enrollment":""},{"nctId":"NCT07428486","phase":"PHASE1","title":"A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-08-17","conditions":"Phase I, FLAG Chemotherapy, Lisaftoclax","enrollment":24},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":475},{"nctId":"NCT03755804","phase":"PHASE2","title":"Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2018-12-12","conditions":"Hodgkin Lymphoma","enrollment":232},{"nctId":"NCT07192770","phase":"","title":"G-CSF-Induced Bone Pain and Supportive Care Approaches","status":"COMPLETED","sponsor":"Ankara Etlik City Hospital","startDate":"2025-09-27","conditions":"Solid Tumors, Chemotherapy-induced Neutropenia","enrollment":225},{"nctId":"NCT06034470","phase":"PHASE1","title":"Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2023-12-18","conditions":"Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome","enrollment":30},{"nctId":"NCT00003042","phase":"PHASE2","title":"Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"1997-05-30","conditions":"Breast Cancer","enrollment":41},{"nctId":"NCT07423728","phase":"NA","title":"CHRONO-MOBILIZE: Chronotherapy of G-CSF for CD34+ Mobilization in Healthy Donors","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2026-03-01","conditions":"Granulocyte Colony-Stimulating Factor (G-CSF) Mobilization","enrollment":160},{"nctId":"NCT04224558","phase":"PHASE1, PHASE2","title":"Stem Cell Transplantation in Crohn's Disease","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2019-11-15","conditions":"Crohn Disease","enrollment":15},{"nctId":"NCT03363373","phase":"PHASE2","title":"Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow","status":"RECRUITING","sponsor":"Y-mAbs Therapeutics","startDate":"2018-04-03","conditions":"Neuroblastoma","enrollment":122},{"nctId":"NCT06431776","phase":"PHASE3","title":"Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).","status":"RECRUITING","sponsor":"Savara Inc.","startDate":"2025-10-22","conditions":"Autoimmune Pulmonary Alveolar Proteinosis","enrollment":5},{"nctId":"NCT06207799","phase":"PHASE2","title":"Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-07-17","conditions":"Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy, Pre-transplant Purging","enrollment":40},{"nctId":"NCT06709495","phase":"PHASE1, PHASE2","title":"Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas","status":"RECRUITING","sponsor":"David S Shulman, MD","startDate":"2025-01-27","conditions":"Sarcoma, Sarcoma, Ewing, Desmoplastic Small Round Cell Tumor","enrollment":63},{"nctId":"NCT05296317","phase":"NA","title":"Evaluation and Modeling of the Effect of G-CSF on the Evolution of Polynuclear Neutrophils During Dense Dose Epirubicin-Cyclophosphamide Regeneration","status":"COMPLETED","sponsor":"Centre Georges Francois Leclerc","startDate":"2022-09-02","conditions":"Localized Breast Cancer","enrollment":97},{"nctId":"NCT03480360","phase":"PHASE3","title":"Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2018-03-28","conditions":"Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia","enrollment":21},{"nctId":"NCT03909412","phase":"PHASE1","title":"Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma","status":"RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2019-10-08","conditions":"Multiple Myeloma","enrollment":18},{"nctId":"NCT04685616","phase":"PHASE3","title":"Brentuximab Vedotin in Early Stage Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University College, London","startDate":"2022-04-14","conditions":"Hodgkin Lymphoma","enrollment":1042},{"nctId":"NCT03147612","phase":"PHASE2","title":"Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-02-08","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia With BCR-ABL1","enrollment":22},{"nctId":"NCT06851767","phase":"PHASE1, PHASE2","title":"Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy","status":"ENROLLING_BY_INVITATION","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-05-09","conditions":"X-linked Severe Combined Immunodeficiency, X-SCID, XSCID","enrollment":18},{"nctId":"NCT03467386","phase":"PHASE1","title":"Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia","status":"SUSPENDED","sponsor":"City of Hope Medical Center","startDate":"2018-03-19","conditions":"Acute Myeloid Leukemia","enrollment":56},{"nctId":"NCT03301350","phase":"PHASE2","title":"Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2017-11-07","conditions":"Breast Cancer, Triple Negative Breast Cancer","enrollment":29},{"nctId":"NCT06158828","phase":"PHASE1, PHASE2","title":"Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-05-15","conditions":"AML, Childhood, Aml, Acute Myeloid Leukemia, Pediatric","enrollment":68},{"nctId":"NCT05799612","phase":"PHASE1","title":"Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-03-22","conditions":"Angiosarcoma","enrollment":""},{"nctId":"NCT05561751","phase":"PHASE2","title":"Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant","status":"COMPLETED","sponsor":"GPCR Therapeutics, Inc.","startDate":"2023-02-13","conditions":"Multiple Myeloma","enrollment":30},{"nctId":"NCT05535166","phase":"PHASE2","title":"Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-12-20","conditions":"Medulloblastoma","enrollment":130},{"nctId":"NCT06528496","phase":"PHASE2","title":"N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-07-22","conditions":"High-risk Neuroblastoma, Neuroblastoma, Childhood Neuroblastoma","enrollment":45},{"nctId":"NCT00458536","phase":"PHASE1, PHASE2","title":"Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2004-10","conditions":"Renal Cancer","enrollment":38},{"nctId":"NCT05753618","phase":"PHASE4","title":"Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy","status":"RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2023-04-17","conditions":"Early-stage Breast Cancer","enrollment":242},{"nctId":"NCT03182244","phase":"PHASE3","title":"A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2017-10-25","conditions":"AML With FLT3 Mutation","enrollment":276},{"nctId":"NCT06594939","phase":"PHASE2","title":"Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2026-03","conditions":"Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":31},{"nctId":"NCT01391962","phase":"PHASE2","title":"Sunitinib or Cediranib for Alveolar Soft Part Sarcoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-07-18","conditions":"Sarcoma, Alveolar Soft Part","enrollment":34},{"nctId":"NCT01511562","phase":"PHASE2","title":"Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2012-09","conditions":"Lymphoma","enrollment":113},{"nctId":"NCT03579875","phase":"PHASE2","title":"Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2018-11-13","conditions":"Fanconi Anemia, Severe Aplastic Anemia, Myelodysplastic Syndromes","enrollment":48},{"nctId":"NCT07377435","phase":"PHASE1","title":"DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM","status":"NOT_YET_RECRUITING","sponsor":"David Avigan","startDate":"2026-07","conditions":"Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma","enrollment":25},{"nctId":"NCT03943901","phase":"PHASE2","title":"Split-Dose R-CHOP for Older Adults With DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2021-02-17","conditions":"Diffuse Large B Cell Lymphoma, DLBCL, Cancer","enrollment":27},{"nctId":"NCT06660368","phase":"PHASE2","title":"BCL2i CLAG-M in R/R Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-11-26","conditions":"Relapsed or Refractory Acute Myeloid Leukemia (AML)","enrollment":52},{"nctId":"NCT03334305","phase":"PHASE1","title":"Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas","status":"TERMINATED","sponsor":"University of Florida","startDate":"2018-05-16","conditions":"Malignant Glioma, High Grade Glioma","enrollment":18},{"nctId":"NCT07374029","phase":"PHASE1","title":"Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML","status":"NOT_YET_RECRUITING","sponsor":"David Avigan","startDate":"2026-07","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse","enrollment":30},{"nctId":"NCT07367178","phase":"PHASE2","title":"Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"MedSIR","startDate":"2026-07","conditions":"Breast Cancer, Advanced HR+/HER2- Breast Cancer, Advanced Triple-Negative Breast Cancer","enrollment":30},{"nctId":"NCT04262843","phase":"PHASE2","title":"Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-02-07","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome","enrollment":33},{"nctId":"NCT03164057","phase":"PHASE2","title":"A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-06-15","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":206},{"nctId":"NCT04898894","phase":"PHASE1","title":"Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2021-11-15","conditions":"Acute Leukemia of Ambiguous Lineage in Relapse, Acute Myeloid Leukemia, in Relapse, Refractory Acute Leukemia of Ambiguous Lineage","enrollment":37},{"nctId":"NCT00336024","phase":"PHASE3","title":"Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-10-22","conditions":"Anaplastic Medulloblastoma, Medulloblastoma, Supratentorial Embryonal Tumor, Not Otherwise Specified","enrollment":91},{"nctId":"NCT04294641","phase":"PHASE2","title":"Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-10","conditions":"Chronic GVHD","enrollment":10},{"nctId":"NCT04959175","phase":"PHASE1, PHASE2","title":"Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-09-23","conditions":"Hematologic Neoplasms","enrollment":320},{"nctId":"NCT03246529","phase":"PHASE3","title":"A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioLineRx, Ltd.","startDate":"2018-03-23","conditions":"Multiple Myeloma","enrollment":180},{"nctId":"NCT03500731","phase":"PHASE1, PHASE2","title":"Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2018-04-19","conditions":"Idiopathic Pulmonary Fibrosis, Emphysema or COPD","enrollment":8},{"nctId":"NCT07059611","phase":"PHASE2","title":"Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2026-04-01","conditions":"Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":34},{"nctId":"NCT04022239","phase":"PHASE1, PHASE2","title":"Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-03-13","conditions":"Hematopoietic and Lymphoid System Neoplasm","enrollment":25},{"nctId":"NCT05544968","phase":"PHASE1","title":"Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2026-03","conditions":"Hodgkin Disease, CD30-Positive Diffuse Large B-Cell Lymphoma, CD30+ Anaplastic Large Cell Lymphoma","enrollment":42},{"nctId":"NCT05317403","phase":"PHASE1","title":"Venetoclax to Augment Epigenetic Modification and Chemotherapy","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2023-03-31","conditions":"Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory","enrollment":40},{"nctId":"NCT07327411","phase":"PHASE2","title":"Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2025-12-27","conditions":"Advanced Refractory Solid Tumors","enrollment":40},{"nctId":"NCT06546098","phase":"","title":"Molgramostim Nebulizer Solution Expanded Access Program Protocol","status":"AVAILABLE","sponsor":"Savara Inc.","startDate":"","conditions":"Autoimmune Pulmonary Alveolar Proteinosis","enrollment":""},{"nctId":"NCT01757626","phase":"PHASE1, PHASE2","title":"Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-12","conditions":"Neuroblastoma","enrollment":186},{"nctId":"NCT03674411","phase":"PHASE2","title":"Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2019-01-02","conditions":"Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Biphenotypic/Undifferentiated Leukemia","enrollment":22},{"nctId":"NCT04240002","phase":"PHASE1, PHASE2","title":"A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)","status":"TERMINATED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2020-09-04","conditions":"Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)","enrollment":9},{"nctId":"NCT07052370","phase":"PHASE1","title":"TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-09-25","conditions":"Hematologic Malignancy","enrollment":30},{"nctId":"NCT02739295","phase":"PHASE4","title":"G-CSF in the Treatment of Toxic Epidermal Necrolysis","status":"COMPLETED","sponsor":"University of Liege","startDate":"2016-07","conditions":"Stevens - Johnson Syndrome","enrollment":10},{"nctId":"NCT00006436","phase":"PHASE2","title":"EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-01-29","conditions":"Lymphoma, AIDS-related, Lymphoma, Large B-Cell, Diffuse","enrollment":68},{"nctId":"NCT06414889","phase":"PHASE1","title":"Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-05-20","conditions":"RUNX1 Familial Platelet Disorder","enrollment":4},{"nctId":"NCT02782546","phase":"PHASE2","title":"Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2017-01-30","conditions":"Acute Myeloid Leukemia","enrollment":60},{"nctId":"NCT05115630","phase":"PHASE2","title":"Off-the-shelf NK Cells + SCT for Myeloid Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-04-08","conditions":"Myeloid Malignancies, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":24},{"nctId":"NCT05088356","phase":"PHASE1","title":"Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft","status":"RECRUITING","sponsor":"Stanford University","startDate":"2021-09-07","conditions":"Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia","enrollment":60},{"nctId":"NCT04902703","phase":"PHASE2","title":"Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2022-06-01","conditions":"Alzheimer Disease","enrollment":42},{"nctId":"NCT06514898","phase":"PHASE1","title":"Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2025-05-05","conditions":"Recurrent Group 3 Medulloblastoma, Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma","enrollment":12},{"nctId":"NCT01850888","phase":"NA","title":"MIBG for Refractory Neuroblastoma and Pheochromocytoma","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2013-12","conditions":"Relapsed Neuroblastoma, Metastatic Pheochromocytoma","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Granocyte","Neulasta"],"phase":"phase_3","status":"active","brandName":"Granulocyte-colony stimulating growth factor","genericName":"Granulocyte-colony stimulating growth factor","companyName":"Hellenic Oncology Research Group","companyId":"hellenic-oncology-research-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Granulocyte-colony stimulating factor (G-CSF) stimulates the bone marrow to produce and release neutrophils, increasing white blood cell counts. Used for Chemotherapy-induced neutropenia, Severe chronic neutropenia, Mobilization of peripheral blood progenitor cells for stem cell transplantation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}